Aziyo Biologics, Inc. provided preliminary sales guidance for the fourth quarter and full year 2022. For the quarter, the company expected net sales of approximately $12.5 million to $12.7 million, an increase of 15%-17% compared to the same prior year period.
For the year, the company expected net sales of approximately $49.0 million to $49.2 million, an increase of 3%-4% compared to the prior year and, after excluding 2021 sales of a discontinued product of $4.9 million, an increase of approximately 15%-16%.